According to clinical data, these are the most common issues: Nausea: Reported by up to 44% of users in some trials, often occurring shortly after an injection or dose increase
Markovic TP, Proietto J, Dixon JB, Rigas G, Deed G, Hamdorf JM, et al
Yang S, Lin C, Zhuo X, Wang J, Rao S, Xu W, et al
Days 114: Dose Titration Begins Side effects are usually most noticeable during the first two weeks as the body adapts to treatment
In conjunction with lifestyle changes, semaglutide has shown significant promise as a tool for weight management
Conclusion Tirzepatide is a good option for long-term treatment